EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Competition‐Based Strategy for the Isolation of an Anti‐Idiotypic Blocking Module and Fine‐Tuning for Conditional Activation of a Therapeutic Antibody

Jan Habermann iD, Dominic Happel iD, Adrian Bloch iD, Charles Shin iD, Harald Kolmar iD

Biotechnology Journal · 2024

DOI: 10.1002/biot.202400432 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biotechnology Journal, 2024. Verfasst von Jan Habermann und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Organic Chemistry and Biochemistry, Technical University of Darmstadt, Darmstadt, Hesse, Germany. Hauptthemen laut MEDLINE: Single-Chain Antibodies, Antibodies, Anti-Idiotypic. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The masking of therapeutic antibodies by the installation of a blocking module that can be removed under certain physiological conditions, is becoming increasingly important to improve their safety and toxicity profile. To gain access to such masking units, we used chicken immunization in combination with yeast surface display and a competition‐based FACS screening campaign to obtain anti‐idiotypic single‐chain Fv (scFv) fragments. This approach promotes the identification of functional masking units, since specificity and high affinity do not necessarily guarantee a paratope blocking effect. This strategy was used to isolate a scFv masking unit for the therapeutic antibody 6G11 (BI‐1206), which is currently in clinical trials for the treatment of B‐cell lymphoma to block the inhibitory Fcγ receptor IIB (CD32b). N‐terminal fusion of the anti‐idiotypic scFv to the 6G11 light chain successfully abolished binding to FcγRIIB in vitro. For conditional activation, a cleavable linker for the tumor‐associated protease MMP‐9 was implemented. To improve demasking efficiency, the affinity of the scFv mask was attenuated through rational design. The substitution of one key amino acid in the masking scFv reduced the affinity toward the 6G11 paratope by factor 10 but still mediated 9800‐fold blocking of receptor binding. Proteolytic demasking allowed full recovery of therapeutic antibody function in vitro, supporting the concept of conditional antibody activation using this anti‐idiotypic binding module.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Single-Chain AntibodiesAntibodies, Anti-IdiotypicAnimalsHumansChickensReceptors, IgG

Stichwörter der Autor:innen

antibody engineeringantibody maskingconditional antibody activationtumor protease

Substanzen

Single-Chain AntibodiesAntibodies, Anti-IdiotypicReceptors, IgG

Autor:innen und Institutionen

  • Institute for Organic Chemistry and Biochemistry, Technical University of Darmstadt, Darmstadt, Hesse, Germany.
  • Department of Biomedical Engineering, Johns Hopkins University, Baltimore, Maryland, USA.
  • Centre for Synthetic Biology, Technical University of Darmstadt, Darmstadt, Hesse, Germany.

ORCID-Profile: Jan Habermann, Dominic Happel, Adrian Bloch, Charles Shin, Harald Kolmar

Förderung

  • Deutsche Forschungsgemeinschaft

Zitieren

APA

Habermann, J., Happel, D., Bloch, A., Shin, C., & Kolmar, H. (2024). A Competition‐Based Strategy for the Isolation of an Anti‐Idiotypic Blocking Module and Fine‐Tuning for Conditional Activation of a Therapeutic Antibody. Biotechnology Journal. https://doi.org/10.1002/biot.202400432

Vancouver

Habermann J, Happel D, Bloch A, Shin C, Kolmar H. A Competition‐Based Strategy for the Isolation of an Anti‐Idiotypic Blocking Module and Fine‐Tuning for Conditional Activation of a Therapeutic Antibody. Biotechnology Journal. 2024. doi:10.1002/biot.202400432

BibTeX
@article{Habermann2024,
  author = {Habermann, Jan and Happel, Dominic and Bloch, Adrian and Shin, Charles and Kolmar, Harald},
  title = {A Competition‐Based Strategy for the Isolation of an Anti‐Idiotypic Blocking Module and Fine‐Tuning for Conditional Activation of a Therapeutic Antibody},
  journal = {Biotechnology Journal},
  year = {2024},
  doi = {10.1002/biot.202400432}
}
Kostenlos starten →